# US 2012/0252699 A1 · Coupled recognition/detection system for in vivo and in vitro use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252699 A1
- Document ID: US20120252699A1
- Status: Published application
- Kind: A1
- Application number: 13/202,250
- Filed: 2010-02-18
- Published: 2012-10-04
- Earliest claimed: 2009-02-18
- Assignees: Cornell University
- Inventors: Samie R. Jaffrey; Jeremy S. Paige
- Web page: https://patentgrep.com/patent/US20120252699A1

## CPC

- C07D 233/96: having three double bonds between ring members or between ring members and non-ring members
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C09B 23/04: one >CH- group, e.g. cyanines, isocyanines, pseudocyanines
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)

## Abstract

The present invention relates to novel fluorophores and their use in combination with novel nucleic acid molecules, called aptamers, that bind specifically to the fluorophore and thereby enhance the fluorescence signal of the fluorophore upon exposure to radiation of suitable wavelength. Molecular complexes formed between the novel fluorophores, novel nucleic acid molecules, and their target molecules are described, and the use of multivalent aptamer constructs as fluorescent sensors for target molecules of interest are also described.

## Claims

### Claim 1

A compound according to formula (I)
wherein,
Q is S or O,
Y is O or N,
Z is N or C(H),
Ar is an aromatic or hetero-aromatic ring system comprising one or two rings;
R1 is present when Y is N, and is a C1-8 hydrocarbon or —(CH2)n—R6 where n is an integer greater than or equal to 1;
R2 is methyl, a mono-, di-, or tri-halo methyl, oxime, O-methyl-oxime, imine, substituted or unsubstituted phenyl with up to three substituents (R7-R9), C2-8 unsaturated hydrocarbon optionally terminated with an amine, amide, carboxylic acid, (meth)acrylate, ester, enone, oxime, O-methyl-oxime, imine, nitromethane, nitrile, ketone, mono-, di-, tri-halo, nitro, cyano, acrylonitrile, acrylonitrile-enoate, acrylonitrile-carboxylate, acrylonitrile-amide, or a second aromatic or hetero-aromatic ring;
R3-R5 are independently selected from H, hydroxy, alkyl, alkoxy, fluoro, chloro, bromo, amino, alkylamino, dialkylamino, alkylthio, cyano, mercapto, nitro, and mono-, di-, or tri-halo methyl, ketone, and carboxylic acid;
R6 is H, a surface-reactive group, a solid surface, or a functional group that can be linked to a surface-reactive group or solid surface;
R7-R9 are independently selected from H, hydroxy, alkyl, alkoxy, fluoro, chloro, bromo, amino, alkylamino, dialkylamino, alkylthio, cyano, mercapto, nitro, and mono-, di-, or tri-halo methyl, ketone, and carboxylic acid;
and salts thereof;
wherein (i) R3-R5 cannot all be H; (ii) when R1 and R2 are methyl, and R4 and R5 are H, R3 is not hydroxy, methoxy, or dimethylamino; and (iii) when R1 is methyl, R4 and R5 are H, and R3 is hydroxy, R2 is not a conjugated hydrocarbon chain.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The compound according to claim 1, wherein Ar is phenyl, Q is oxygen, and Z and Y are nitrogen.

### Claim at position 4

5-14. (canceled)

### Claim 15

A nucleic acid molecule comprising a first domain that binds specifically to a fluorophore comprising a methyne bridge between a substituted aromatic ring system and a substituted imidazol(thi)one, oxazol(thi)one, pyrrolin(thi)one, or furan(thi)one ring, wherein binding of the nucleic acid molecule to the fluorophore substantially enhances fluorescence of the fluorophore upon exposure to radiation of suitable wavelength.

### Claim at position 6

16-17. (canceled)

### Claim 18 (depends on 15)

The nucleic acid molecule according to claim 15, wherein the first domain comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-30.

### Claim 19 (depends on 15)

The nucleic acid molecule according to claim 15 further comprising one or more additional first domains that bind specifically to the fluorophore.

### Claim 20 (depends on 15)

The nucleic acid molecule according to claim 15, wherein binding of the nucleic acid molecule to the fluorophore is ion dependent, temperature dependent, or pH dependent.

### Claim at position 10

21-23. (canceled)

### Claim 24 (depends on 15)

The nucleic acid molecule according to claim 15 further comprising a second domain that binds specifically to a target molecule that is distinct of the fluorophore.

### Claim at position 12

25-26. (canceled)

### Claim 27 (depends on 24)

The nucleic acid molecule according to claim 24, wherein the first domain binds to the compound only after the second domain binds to the target molecule.

### Claim at position 14

28-30. (canceled)

### Claim 31 (depends on 15)

The nucleic acid molecule according to claim 15, wherein the nucleic acid molecule comprises RNA, DNA, or a modified nucleic acid.

### Claim at position 16

32-34. (canceled)

### Claim 35 (depends on 15)

A kit comprising:
a fluorophore comprising a methyne bridge between a substituted aromatic ring system and a substituted imidazol(thi)one, oxazol(thi)one, pyrrolin(thi)one, or furan(thi)one ring; and
a plurality of nucleic acid molecules according to claim 15, each of the plurality of nucleic acid molecules, upon binding, causes a different emission profile by the fluorophore.

### Claim 36

(canceled)

### Claim 37 (depends on 35)

The kit according to claim 35, wherein the plurality of nucleic acid molecules comprise two or more of 4-(3,4,5-trimethoxybenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-hydroxy-3,5-dimethoxybenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(3,5-difluoro-4-hydroxybenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(3,5-difluoro-4-hydroxy-benzylidene)-1-methyl-2-(O-methyl)oxime-imidazolin-5-one; 4-(3,5-dichloro-4-hydroxybenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(3,5-dibromo-4-hydroxybenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(2-hydroxybenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(2-methoxybenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(3-fluoro-4-hydroxy-5-methoxybenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-(dimethylamino)benzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-(t-butylthio)benzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-(methylthio)benzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-cyanobenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(3,5-difluoro-4-acetate)benzylidene-1,2-dimethyl-imidazol-5one; 4-(4-hydroxy-3-nitrobenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-methoxy-3-nitrobenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-bromobenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-chlorobenzylidene)-1,2-dimethyl-imidazol-5-one; 4-(4-hydroxybenzylidene)-1,2-dimethyl-imidazol-5-one; 4-((indol-7-yl)methylene)-1,2-dimethyl-imidazole-5-one; 4-((indol-3-yl)methylene)-1,2-dimethyl-imidazole-5-one; 4-((indol-3-yl)methylene)-1-methyl-2-phenyl-imidazole-5-one; 4-(4-hydroxy-3,5-dimethoxybenzylidene)-1-methyl-2-phenyl-imidazole-5-one; 4-(4-(dimethylamino)benzylidene)-1-methyl-2-phenyl-imidazole-5-one; 4-(4-hydroxybenzylidene)-2-acetyl-1-methyl-imidazole-5-one; 4-(4-hydroxybenzylidene)-1-methyl-2-prop-1-enyl-imidazole-5-one; 3-(4-(4-hydroxybenzylidene)-4,5-dihydro-1-methyl-5-oxo-imidazol-2-yl)acrylamide; 3-(4-(4-hydroxybenzylidene)-4,5-dihydro-1-methyl-5-oxo-imidazol-2-yl)acrylic acid; and methyl 3-(4-(4-hydroxybenzylidene)-4,5-dihydro-1-methyl-5-oxo-imidazol-2-yl)acrylate.

### Claim 38 (depends on 35)

The kit according to claim 35, wherein the plurality of nucleotide molecules are immobilized to a substrate in an array.

### Claim 39

(canceled)

### Claim 40 (depends on 35)

The kit according to claim 35, wherein the plurality of nucleic acid molecules are present as a mixture of two or more nucleic acid molecules.

### Claim 41 (depends on 35)

The kit according to claim 35, wherein
the kit comprises a plurality of fluorophores comprising a methyne bridge between a substituted aromatic ring system and a substituted imidazol(thi)one, oxazol(thi)one, pyrrolin(thi)one, or furan(thi)one ring; and
wherein the plurality of nucleic acid molecules each bind to at least one of the plurality of fluorophores.

### Claim at position 24

42-46. (canceled)

### Claim 47 (depends on 15)

A molecular complex comprising:
a fluorophore comprising a methyne bridge between a substituted aromatic ring system and a substituted imidazol(thi)one, oxazol(thi)one, pyrrolin(thi)one, or furan(thi)one ring; and
a nucleic acid molecule according to claim 15 specifically bound to the fluorophore, wherein the fluorophore has substantially enhanced fluorescence, in comparison to the fluorophore prior to specific binding, upon exposure to radiation of suitable wavelength.

### Claim 48 (depends on 47)

The molecular complex according to claim 47, wherein the fluorophore comprises a structure according to formula (I):
wherein,
Q is S or O,
Y is O or N,
Z is N or C(H),
Ar is an aromatic or hetero-aromatic ring system comprising one or two rings;
R1 is present when Y is N, and is a C1-8 hydrocarbon or —(CH2)n—R6 where n is an integer greater than or equal to 1;
R2 is methyl, a mono-, di-, or tri-halo methyl, oxime, O-methyl-oxime, imine, substituted or unsubstituted phenyl with up to three substituents (R7-R9), C2-8 unsaturated hydrocarbon optionally terminated with an amine, amide, carboxylic acid, (meth)acrylate, ester, enone, oxime, O-methyl-oxime, imine, nitromethane, nitrile, ketone, mono-, di-, tri-halo, nitro, cyano, acrylonitrile, acrylonitrile-enoate, acrylonitrile-carboxylate, acrylonitrile-amide, or a second aromatic or hetero-aromatic ring;
R3-R5 are independently selected from H, hydroxy, alkyl, alkoxy, fluoro, chloro, bromo, amino, alkylamino, dialkylamino, alkylthio, cyano, mercapto, nitro, and mono-, di-, or tri-halo methyl, ketone, and carboxylic acid;
R6 is H, a surface-reactive group, a solid surface, or a functional group that can be linked to a surface-reactive group or solid surface;
R7-R9 are independently selected from H, hydroxy, alkyl, alkoxy, fluoro, chloro, bromo, amino, alkylamino, dialkylamino, alkylthio, cyano, mercapto, nitro, and mono-, di-, or tri-halo methyl, ketone, and carboxylic acid;
and salts thereof

### Claim 49 (depends on 47)

The molecular complex according to claim 47, wherein
(i) is methyl, ethyl or (CH2)n—R6, R2 is methyl, R3 is 3-methoxy, R4 is 4-hydroxy, and R5 is 5-methoxy; and the nucleic acid molecule is selected from the group of SEQ ID NOS: 1-15;
(ii) R1 is methyl, ethyl or (CH2)n—R6, R2 is methyl, R3 is 3-halo, R4 is 4-hydroxy, and R5 is 5-halo, where the halo group is fluoro, chloro, or bromo; and the nucleic acid molecule is selected from the group of SEQ ID NOS: 16-19;
(iii) R1 is methyl or (CH2)n—R6, R2 is methyl, R3 is 2-hydroxy, and R4 and R5 are hydrogen; and the nucleic acid molecule is selected from the group of SEQ ID NOS: 20-23; or
(iv) R1 is methyl or (CH2)n—R6, R2 is methyl, R3 is 2-hydroxy, R4 is 4-dimethylamino, and R5 are hydrogen; and the nucleic acid molecule is selected from the group of SEQ ID NOS: 24-30.

### Claim at position 28

50-53. (canceled)

### Claim 54 (depends on 47)

The molecular complex according to claim 47, wherein the nucleic acid molecule comprises RNA, DNA or a modified nucleic acid.

### Claim 55

(canceled)

### Claim 56 (depends on 47)

The molecular complex according to claim 47, wherein the nucleic acid molecule further comprises a second domain that binds specifically to a target molecule that is distinct of the fluorophore.

### Claim at position 32

57-59. (canceled)

### Claim 60 (depends on 56)

The molecule complex according to claim 56, wherein the first domain binds to the fluorophore only after binding of the second domain to the target molecule, the molecular complex further comprising the target molecule bound by the second domain.

### Claim at position 34

61-62. (canceled)

### Claim 63 (depends on 47)

A host cell containing the molecular complex according to claim 47.

### Claim at position 36

64-65. (canceled)

### Claim 66 (depends on 31)

A constructed DNA molecule comprising a first region encoding an RNA molecule according to claim 31.

### Claim 67 (depends on 66)

The constructed DNA molecule according to claim 66 further comprising a promoter operably coupled to the first region to control expression of the RNA molecule.

### Claim at position 39

68-70. (canceled)

### Claim 71 (depends on 66)

The constructed DNA molecule according to claim 66, further comprising a second region that is linked to the first region, the second region encoding an RNA transcript of interest, whereby transcription of the constructed DNA molecule forms an RNA molecule that includes the RNA transcript of interest joined to the RNA molecule that binds specifically to a fluorophore.

### Claim 72 (depends on 66)

An expression system comprising an expression vector into which is inserted a DNA molecule according to claim 66.

### Claim 73

(canceled)

### Claim 74 (depends on 72)

A transgenic host cell comprising the expression system of claim 72.

### Claim at position 44

75-91. (canceled)

### Claim 92 (depends on 60)

A method of detecting a target molecule comprising:
forming a molecular complex according to claim 60;
exciting the fluorophore with radiation of appropriate wavelength; and
detecting fluorescence by the fluorophore, whereby fluorescence by the fluorophore identifies presence of the target molecule.

### Claim at position 46

93-104. (canceled)

### Claim 105 (depends on 67)

A method of measuring transcription by a promoter of interest in a cell, the method comprising:
introducing a DNA construct according to claim 67 into a cell;
introducing into the cell a fluorophore in a substantially non-fluorescent form;
introducing an agent that modulates transcription of the DNA construct into the cell; and
detecting fluorescence by the fluorophore within the cell, whereby the level of fluorescence correlates with the level of transcription for the DNA construct and the effect of the agent in modulating the level of transcription.

### Claim 106 (depends on 67)

A method of measuring transcription by a promoter of interest, the method comprising:
introducing into a cell a DNA construct according to claim 67 and an agent that modulates transcription of the DNA construct;
recovering RNA transcripts from the cell;
introducing a fluorophore in a substantially non-fluorescent form to the recovered RNA transcripts; and
detecting fluorescence by the fluorophore, whereby the level of fluorescence correlates with the level of transcription by the DNA construct and the effect of the agent in modulating the level of transcription.

### Claim at position 49

107-132. (canceled)
